These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29894291)

  • 1. Regulation of LRRK2: insights from structural and biochemical analysis.
    Gilsbach BK; Eckert M; Gloeckner CJ
    Biol Chem; 2018 Jun; 399(7):637-642. PubMed ID: 29894291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover.
    Deyaert E; Wauters L; Guaitoli G; Konijnenberg A; Leemans M; Terheyden S; Petrovic A; Gallardo R; Nederveen-Schippers LM; Athanasopoulos PS; Pots H; Van Haastert PJM; Sobott F; Gloeckner CJ; Efremov R; Kortholt A; Versées W
    Nat Commun; 2017 Oct; 8(1):1008. PubMed ID: 29044096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
    Park Y; Liao J; Hoang QQ
    Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
    Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ
    Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease.
    Herbst S; Lewis PA
    Biochem J; 2021 Jul; 478(14):2945-2951. PubMed ID: 34328508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First model of dimeric LRRK2: the challenge of unrevealing the structure of a multidomain Parkinson's-associated protein.
    Guaitoli G; Gilsbach BK; Raimondi F; Gloeckner CJ
    Biochem Soc Trans; 2016 Dec; 44(6):1635-1641. PubMed ID: 27913672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.
    Huang X; Wu C; Park Y; Long X; Hoang QQ; Liao J
    FASEB J; 2019 Apr; 33(4):4814-4823. PubMed ID: 30592623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The unconventional G-protein cycle of LRRK2 and Roco proteins.
    Terheyden S; Nederveen-Schippers LM; Kortholt A
    Biochem Soc Trans; 2016 Dec; 44(6):1611-1616. PubMed ID: 27913669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closing the structure-to-function gap for LRRK2.
    Tokars V; Chen C; Parisiadou L
    Trends Biochem Sci; 2022 Mar; 47(3):187-188. PubMed ID: 34756665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the Influence of Specific Splicing Events on the Structural Organization of
    Vlachakis D; Labrou NE; Iliopoulos C; Hardy J; Lewis PA; Rideout H; Trabzuni D
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
    Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
    J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine-rich repeat kinase 2 and Parkinson's disease.
    Kang UB; Marto JA
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The LRRK2 N-terminal domain influences vesicle trafficking: impact of the E193K variant.
    Marku A; Carrion MDP; Pischedda F; Marte A; Casiraghi Z; Marciani P; von Zweydorf F; Gloeckner CJ; Onofri F; Perego C; Piccoli G
    Sci Rep; 2020 Mar; 10(1):3799. PubMed ID: 32123243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 and Rab GTPases.
    Pfeffer SR
    Biochem Soc Trans; 2018 Dec; 46(6):1707-1712. PubMed ID: 30467121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roco Proteins: GTPases with a Baroque Structure and Mechanism.
    Wauters L; Versées W; Kortholt A
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.